Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

751 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
Harrington RA, Sane DC, Califf RM, Sigmon KN, Abbottsmith CW, Candela RJ, Lee KL, Topol EJ. Harrington RA, et al. J Am Coll Cardiol. 1994 Mar 15;23(4):891-8. doi: 10.1016/0735-1097(94)90634-3. J Am Coll Cardiol. 1994. PMID: 8106694 Free article. Clinical Trial.
Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy.
Alexander JH, Harrington RA, Tuttle RH, Berdan LG, Lincoff AM, Deckers JW, Simoons ML, Guerci A, Hochman JS, Wilcox RG, Kitt MM, Eisenberg PR, Califf RM, Topol EJ, Karsh K, Ruzyllo W, Stepinska J, Widimsky P, Boland JB, Armstrong PW. Alexander JH, et al. Among authors: harrington ra. Am J Cardiol. 1999 Apr 15;83(8):1147-51. doi: 10.1016/s0002-9149(99)00049-1. Am J Cardiol. 1999. PMID: 10215274 Clinical Trial.
Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience.
McClure MW, Berkowitz SD, Sparapani R, Tuttle R, Kleiman NS, Berdan LG, Lincoff AM, Deckers J, Diaz R, Karsch KR, Gretler D, Kitt M, Simoons M, Topol EJ, Califf RM, Harrington RA. McClure MW, et al. Among authors: harrington ra. Circulation. 1999 Jun 8;99(22):2892-900. doi: 10.1161/01.cir.99.22.2892. Circulation. 1999. PMID: 10359733 Clinical Trial.
Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
Alexander JH, Sparapani RA, Mahaffey KW, Deckers JW, Newby LK, Ohman EM, Corbalán R, Chierchia SL, Boland JB, Simoons ML, Califf RM, Topol EJ, Harrington RA. Alexander JH, et al. Among authors: harrington ra. JAMA. 2000 Jan 19;283(3):347-53. doi: 10.1001/jama.283.3.347. JAMA. 2000. PMID: 10647797
Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease.
Harrington RA, Armstrong PW, Graffagnino C, Van De Werf F, Kereiakes DJ, Sigmon KN, Card T, Joseph DM, Samuels R, Granett J, Chan R, Califf RM, Topol EJ. Harrington RA, et al. Circulation. 2000 Aug 15;102(7):728-35. doi: 10.1161/01.cir.102.7.728. Circulation. 2000. PMID: 10942739 Clinical Trial.
751 results